BIND Therapeutics Inc (NASDAQ:BIND) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 12 month consensus target price of $7.50 for the company and are anticipating that the company will post ($0.61) EPS for the current quarter, according to Zacks. Zacks has also given BIND Therapeutics an industry rank of 73 out of 265 based on the ratings given to its competitors.
BIND Therapeutics (NASDAQ:BIND) opened at 1.92 on Thursday. The company’s 50-day moving average price is $1.66 and its 200 day moving average price is $3.27. BIND Therapeutics has a 52-week low of $1.14 and a 52-week high of $8.10. The firm’s market capitalization is $39.90 million.
BIND Therapeutics (NASDAQ:BIND) last issued its earnings results on Tuesday, March 15th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.12. The company earned $6.40 million during the quarter, compared to analyst estimates of $3.35 million. Equities analysts predict that BIND Therapeutics will post ($1.89) earnings per share for the current fiscal year.
BIND has been the topic of a number of research analyst reports. Zacks Investment Research upgraded BIND Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Wednesday, January 6th. Oppenheimer restated an “outperform” rating on shares of BIND Therapeutics in a research report on Wednesday, February 17th. JPMorgan Chase & Co. decreased their price target on BIND Therapeutics from $9.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Wednesday, March 9th. Finally, JMP Securities increased their price target on BIND Therapeutics from $9.00 to $25.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 15th.
BIND Therapeutics, Inc is a clinical-stage nano-medicine platform company. The Company is engaged in developing a pipeline of Accurins. The Company utilizes its Medicinal Nano-engineering platform to develop a pipeline of Accurins in oncology. The Company’s products include BIND-014 and BIND-510. The Company’s lead drug candidate BIND-014 is a prostate-specific membrane antigen (NASDAQ:BIND)-targeted Accurin that contains docetaxel, a clinically validated cancer chemotherapy drug.